Following the news of the $3 billion settlement between the government and GlaxoSmithKline for illegal promotion of prescription drugs for unapproved uses, Mr. Goozner say many assume off-label promotion will become a thing of the past. However, he wrote, just because companies are more focused on compliance with the law doesn’t mean they aren’t still promoting the drugs.
Related Articles on Pharmaceuticals:
AMA Adopts New Policy for Drug Shortages
Senate Proposal Would Allow FDA to Fast Track Drugs for Unmet Needs
10 Recent FDA Drug and Medical Device Decisions
